Oravig (miconazole) NDC 61825-303

NDC codes

FDA NDC Directory

Product NDC (as listed)61825-303Labeler and product segments. Claims need a package NDC.

Product NDC at billing width61825-0303Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
61825-303-14	61825030314	14 TABLET in 1 BOTTLE (61825-303-14)Marketed from Dec 31, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oravig
Generic name (nonproprietary): miconazole
Active ingredients: Miconazole — 50 mg/1
Dosage form: Tablet
Route: Buccal
Labeler: Galt Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022404
Marketing start: Dec 31, 2021
Listing expires: Dec 31, 2027
Other FDA classes: Azoles (Chemical structure)
Identifiers: Product ID 61825-303_47da8a7f-0d47-f1cd-e063-6394a90a84adSPL ID 47da8a7f-0d47-f1cd-e063-6394a90a84adSPL set ID dc2427ff-e566-4b48-b289-9e51c011250aRxCUI 998548, 998550UNII 7NNO0D7S5M
Pharmacologic class: Azole Antifungal

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Buccal products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N461825030314 followed by a unit qualifier and the quantity

Package 61825-0303-14. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 8, 2026.

Indications (excerpt from the label)

ORAVIG is indicated for the local treatment of oropharyngeal candidiasis (OPC) in adults. ORAVIG is an azole antifungal indicated for the local treatment of oropharyngeal candidiasis in adults.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)